To strengthen its therapeutic antibody pipeline, Regeneron has signed a license and collaboration agreement with ModeX Therapeutics to develop multispecific antibody candidates that target multiple biological pathways to address diverse therapeutic indications such as immunology, oncology, and metabolic diseases. Through the deal, which includes US$7 M in upfront and near-term milestone payments, the companies will leverage ModeX’s MSTAR platform and Regeneron’s proprietary binders.